VISION trial

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor, Johann S. de Bono, Kim N. et al. · New England Journal of Medicine · 2021 · 2.6K citations · Full text

Medicine, Oncology, Radiation Oncology +17

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +12

Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients

Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo et al. · Clinical Nuclear Medicine · 2019 · 113 citations

Medicine, Nuclear Medicine, Oncology +17

Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort

Sonam Suman, Rahul V. Parghane, Amit Joshi et al. · British Journal of Radiology · 2019 · 62 citations · Full text

Medicine, Nuclear Medicine, Oncology +17